Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Immune checkpoint inhibitors (ICIs), though revolutionary in cancer treatment ... In addition, 8 subgroups were assessed: (1) patients with melanoma, (2) patients without a history of cardiovascular ...

Background: The combination therapy of BRAF inhibitors (BRAFis) and MEK inhibitors (MEKis) has been approved as a first-line treatment for metastatic melanoma with BRAF V600 mutants. Recently, BRAF ...

BRAF, a member of a serine/threonine ... currently utilized for the therapy of malignant metastatic melanoma. They include RAF inhibitors, such as sorafenib and vemurafenib, or MEK inhibitors ...

Patients with melanoma and colorectal cancer ... currently investigating the possibility of BRAF degraders since BRAF/MEK inhibitor combinations are being utilized to treat a variety of cancer ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RASand BRAF genes (RAS/BRAF wild-type) are typically treated with EGFR inhibitors.

there were no approved biomarker-driven therapies specifically indicated for people with previously untreated BRAF V600E -mutant mCRC. Braftovi is an oral small molecule kinase inhibitor that targets ...

This BRAF/CRAF inhibitor is being evaluated in a Phase 3 study called SEACRAFT-2 as part of a combination therapy with Mikinist (trametinib) from Novartis to treat NRASm melanoma. The primary ...

all four class 1 MAP2K1-mutant tumors that experienced a response to treatment were in the context of coexisting BRAF V600E mutations treated with BRAF inhibitors. Class 2 MAP2K1 mutants fall between ...

We have been fortunate that inhibitors targeting the pathways affected by these mutations already exist. Building on top of the work of other research teams—science and research is like being a ...

This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text component.